Table 5. The Diagnostic Power for Differentiating Gastric Carcinoma from the Controls in the Retrospective Verification Group.
| Cutoff value |
Actual status, No. of subjects |
|||||||
|---|---|---|---|---|---|---|---|---|
| Test | GC+ | GC- | Sensitivity, % | Specificity, % | PPV, % |
NPV, % |
Accuracy, % | |
| CEA (5 ng/mL) | GC+ | 8 | 0 | 40.00 | 100.00 | 100.00 | 62.50 | 70.00 |
| GC- | 12 | 20 | ||||||
| CA19-9 (37 U/mL) | GC+ | 8 | 1 | 40.00 | 95.00 | 88.89 | 61.29 | 67.50 |
| GC- | 12 | 19 | ||||||
| CA125 (40 U/mL) | GC+ | 6 | 0 | 30.00 | 100.00 | 100.00 | 58.82 | 65.00 |
| GC- | 14 | 20 | ||||||
| CA72-4 (9.8 U/mL) | GC+ | 6 | 0 | 30.00 | 100.00 | 100.00 | 58.82 | 65.00 |
| GC- | 14 | 20 | ||||||
| GCglycoA (-0.77) | GC+ | 17 | 3 | 85.00 | 85.00 | 85.00 | 85.00 | 85.00 |
| GC- | 3 | 17 | ||||||
Abbreviations: + positive; - negative; GC, gastric carcinoma; GCglycoA, N-glycan marker-based gastric cancer diagnostic model A; NPV, negative predictive value; PPV, positive predictive value.